Answer
Ivacaftor is not recommended after organ transplantation in people with cystic fibrosis because it has not been studied in this population, either alone or in combination regimens with tezacaftor/ivacaftor or ivacaftor/tezacaftor/elexacaftor.
Sources for this answer
- Kalydeco 150 mg film-coated tabletsVertex Pharmaceuticals (Europe) Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 35Document updated
Sources checked